TherapeuticsMD (TXMD) Cash from Discontinued Operations (2010 - 2026)
TherapeuticsMD (TXMD) posted Cash from Discontinued Operations of 8000.0 for Q1 2026, down 14.29% on a QoQ basis from 7000.0 in Q4 2025, and up 38.46% year-over-year from 5777.78 in Q1 2025.
TherapeuticsMD (TXMD) Cash from Discontinued Operations (2010 - 2026) Analysis & Trends
TherapeuticsMD's Cash from Discontinued Operations history runs 6 years deep, the most recent figure standing at 8000.0 for Q1 2026.
- Quarterly Cash from Discontinued Operations rose 38.46% year-over-year to 8000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 25000.0 (up 96.38% YoY) and the FY2025 annual result came in at 30000.0, up 93.15% from the prior year.
- Cash from Discontinued Operations was 8000.0 for Q1 2026 at TherapeuticsMD, down from 7000.0 in the prior quarter.
- Across five years, Cash from Discontinued Operations topped out at 136529000.0 in Q2 2022 and bottomed at 131010000.0 in Q4 2022.
- A 5-year average of 2292529.41 and a median of 57000.0 in 2025 frame the typical range for Cash from Discontinued Operations.
- Peak annual rise in Cash from Discontinued Operations reached 148.93% in 2023, while the deepest fall reached 110.01% in 2023.
- TherapeuticsMD's Cash from Discontinued Operations stood at 131010000.0 in 2022, then soared by 97.8% to 2881000.0 in 2023, then surged by 99.83% to 5000.0 in 2024, then tumbled by 40.0% to 7000.0 in 2025, then dropped by 14.29% to 8000.0 in 2026.
- Business Quant data shows TXMD's Cash from Discontinued Operations at 8000.0 in Q1 2026, 7000.0 in Q4 2025, and 47000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | TherapeuticsMD | 280,159.99 | -8.14 Mn | - | -8,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,000.00 |
| Mar 31, 2026 | -8,000.00 |
| Dec 31, 2025 | -7,000.00 |
| Dec 31, 2025 | -7,000.00 |
| Sep 30, 2025 | 47,000.00 |
| Sep 30, 2025 | 47,000.00 |
| Jun 30, 2025 | -57,000.00 |
| Jun 30, 2025 | -57,000.00 |
| Mar 31, 2025 | -13,000.00 |
| Mar 31, 2025 | -13,000.00 |
| Dec 31, 2024 | -5,000.00 |
| Dec 31, 2024 | -5,000.00 |
| Sep 30, 2024 | -114,000.00 |
| Sep 30, 2024 | -114,000.00 |
| Jun 30, 2024 | -559,000.00 |
| Jun 30, 2024 | -559,000.00 |
| Mar 31, 2024 | 240,000.00 |
| Mar 31, 2024 | 240,000.00 |
| Dec 31, 2023 | -2.88 Mn |
| Dec 31, 2023 | -2.88 Mn |